- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07723508
BeauSaki Bird's Nest Peptide Efficacy
Efficacy Evaluation of BeauSaki Edible Bird's Best Peptide Product
The goal of this clinical trial is to learn whether BeauSaki Edible Bird's Nest Peptide Product can improve facial skin conditions in healthy adult participants. The main questions it aims to answer are:
Can daily intake of the edible bird's nest peptide product improve facial skin hydration, elasticity, brightness, wrinkles, pores, spots, redness, and skin texture after 8 weeks?
Is the edible bird's nest peptide product well tolerated by participants during the study period?
Researchers will compare participants who take the edible bird's nest peptide capsule with participants who take a placebo capsule without edible bird's nest to see if the product improves facial skin conditions.
Participants will:
- Take one capsule daily for 8 weeks.
- Visit the study site at baseline, week 4, and week 8 for non-invasive facial skin assessments.
- Cleanse their face with water and rest under room temperature conditions for 30 minutes before each skin assessment.
- Complete a brief questionnaire about perceived skin condition and product satisfaction at baseline, week 4, and week 8.
- Have facial photographs taken for skin condition evaluation, with identifiable areas masked before disclosure.
Studieoversikt
Status
Forhold
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Taiwan
-
Tainan, Taiwan, Taiwan, 71710
- Chia Nan University of Pharmacy & Science
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Participants aged over 18 years.
Exclusion Criteria:
- Individuals who are unwilling to participate voluntarily.
- Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
- Individuals with known allergies to cosmetics, drugs, or foods.
- Pregnant or breastfeeding individuals.
- Individuals taking medications for chronic diseases.
- Students taught by the principal investigator.
- Individuals unwilling to allow their study-related photographs to be disclosed. Vegetarians.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: BeauSaki Edible Bird's Nest Peptide Group
Participants in this group will take one capsule of BeauSaki Edible Bird's Nest Peptide Product daily for 8 weeks.
|
Participants will take one capsule daily for 8 weeks.
|
|
Placebo komparator: Placebo Group
Participants in this group will take one placebo capsule without edible bird's nest daily for 8 weeks.
|
Participants will take one placebo capsule without edible bird's nest daily for 8 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Facial Skin Analysis Parameters
Tidsramme: Baseline, week 4, and week 8
|
VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots, wrinkles, texture, pores, UV spots, brown Spots, red areas, porphyrins. Units: arbitrary units. Facial skin condition will be assessed using non-invasive image-based facial skin analysis. Changes from baseline will be evaluated at week 4 and week 8. |
Baseline, week 4, and week 8
|
|
Skin Moisture
Tidsramme: Baseline, week 4, and week 8
|
Skin moisture meter (VapoMeter) was utilized to measure skin moisture.
Units: g/m²h Facial skin condition will be assessed using non-invasive image-based facial skin analysis.
Changes from baseline will be evaluated at week 4 and week 8.
|
Baseline, week 4, and week 8
|
|
Skin elasticity
Tidsramme: Baseline, week 4, and week 8
|
Skin elastometer (Soft Plus) was utilized to measure skin elasticity.
Units: arbitrary units.
Facial skin condition will be assessed using non-invasive image-based facial skin analysis.
Changes from baseline will be evaluated at week 4 and week 8.
|
Baseline, week 4, and week 8
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- TMSHIRB25-104-B
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .